Kiyoshi Hasegawa, Tadatoshi Takayama, Masayoshi Ijichi, Yutaka Matsuyama, Hiroshi Imamura, Keiji Sano, Yasuhiko Sugawara, Norihiro Kokudo, Masatoshi Makuuchi – 27 September 2006 – Frequent recurrence of hepatocellular carcinoma (HCC) after surgery remains a major clinical problem. This randomized controlled trial evaluated whether postoperative adjuvant therapy with oral uracil‐tegafur (UFT) prevents recurrence of HCC.

Zhi Ming, Yi‐Jun Fan, Xi Yang, W. Wayne Lautt – 27 September 2006 – Acute liver injury is associated with renal insufficiency, whose mechanism may be related to activation of the hepatorenal reflex. We previously showed that intrahepatic adenosine is involved in activation of the hepatorenal reflex to restrict urine production in both healthy rats and in rats with cirrhosis. The aim of the present study was to test the hypothesis that activation of intrahepatic adenosine receptors is involved in the pathogenesis of the renal insufficiency seen in acute liver injury.

Richard B. Freeman, Abigail Mithoefer, Robin Ruthazer, Khanh Nguyen, Anthony Schore, Ann Harper, Erick Edwards – 26 September 2006 – Assignment of liver allocation priority for hepatocellular carcinoma is predicated on accurate imaging staging. We analyzed radiographically defined stage (radiologic stage [RS]) at listing and most recent extension and pathologic stage (PS) data from 789 liver transplant recipients for whom no pretransplant ablative treatment was given. There were no predetermined imaging or pathological protocols in this retrospective analysis of wait list data.

Teh‐Ia Huo, Shou‐Dong Lee, Jaw‐Ching Wu – 26 September 2006

Gary Levy, Gian Luca Grazi, Fernando Sanjuan, Youmin Wu, Ferdinand Mühlbacher, Didier Samuel, Styrbjorn Friman, Robert Jones, Guido Cantisani, Federico Villamil, Umberto Cillo, Pierre Alain Clavien, Goran Klintmalm, Gerd Otto, Stephen Pollard, P Aiden McCormick, LIS2T Study Group – 26 September 2006 – The LIS2T study was an open‐label, multicenter study in which recipients of a primary liver transplant were randomized to cyclosporine microemulsion (CsA‐ME) (Neoral) (n = 250) (monitoring of blood concentration at 2 hours postdose) C2 or tacrolimus (n = 245) (monitoring of trough drug blood l

Jonathan A. Schneider, Edward A. White, Derek C. Welch, LeAnn S. Stokes, David S. Raiford – 26 September 2006 – A 64‐year‐old man with portal hypertension secondary to hepatic nodular transformation was awaiting liver transplantation when he presented with severe, unrelenting abdominal pain, fever, and hypotension. Computed tomographyrevealed pneumatosis within the cecum and ascending colon. Because of his advanced liver disease and the perceived high likelihood of a poor outcome after colonic resection, he was managed medically.

Asma Poonawala Khapra, Kaushik Agarwal, Maria Isabel Fiel, Nickolas Kontorinis, Sabera Hossain, Sukru Emre, Thomas D. Schiano – 26 September 2006 – Studies have suggested that the use of hepatitis C virus (HCV)‐positive (HCV+) donor allografts has no impact on survival. However, no studies have examined the effect that HCV+ donor histology has upon recipient and graft survival. We evaluated the clinical outcome and impact of histological features in HCV patients transplanted using HCV+ livers.

Joon‐Shik Moon, Nizar Souayah – 26 September 2006 – Guillain‐Barré syndrome (GBS) has been rarely reported after liver transplantation and generally has good outcome. We report a liver transplant patient on FK506 (tacrolimus) who developed GBS 6 months after liver transplantation. There was no evidence of liver rejection or active infection. Despite treatment with intravenous immunoglobulin, the patient expired. GBS occurred despite downregulation of T cells by FK506, suggesting that humoral dysfunction might be the predominant mechanism of GBS in this report.

Amadeo Marcos, Fadi Lakkis, Thomas E. Starzl – 26 September 2006

Frederik Nevens, Jane N. Zuckerman, Andrew K. Burroughs, Maria‐Christina Jung, José M. Bayas, Birgit Kallinowski, Enrique Fraga Rivas, Christophe Duvoux, Peter Neuhaus, Faouzi Saliba, Maria Buti, Jean‐Pierre Zarski, Fernando Pons, Claire Vanlemmens, Virginie Hamtiaux, Michel Stoffel – 26 September 2006 – Patients with chronic liver disease are at higher risk of hepatitis B (HB) virus infection before and after liver transplantation, and they commonly have a suboptimal immune response to HB vaccines.